The TLR4 antagonist CRX‐526, a synthetic lipid A mimetic molecule, also known as an aminoalkyl‐glucosaminide‐phosphate (AGP), has therapeutic potential to attenuate renal injuries and slow the progression of advanced diabetic nephropathy in wild‐type and endothelial nitric oxide synthase (eNOS) knockout mice.87 This evidence concerns the gene NOS3 and diabetic kidney disease.